Tryngolza (olezarsen) is a once-monthly antisense oligonucleotide (ASO) injection that silences the APOC3 gene, reducing triglycerides by 60–70%. FDA-approved in March 2025 for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia to reduce the risk of pancreatitis.
Tryngolza (olezarsen) was FDA-approved in March 2025, developed by Ionis Pharmaceuticals in partnership with AstraZeneca. It is an antisense oligonucleotide (ASO) — a synthetic strand of DNA-like molecules that binds to APOC3 messenger RNA in liver cells and prevents it from being translated into protein. The result is a profound and sustained reduction in triglyceride levels.
How Does Tryngolza Work?
Like plozasiran (Redemplo), olezarsen targets APOC3 — but uses a different molecular mechanism:
- Antisense oligonucleotide (ASO): A short, single-stranded synthetic nucleic acid that binds to the complementary APOC3 mRNA sequence
- When the ASO binds, it recruits RNase H, an enzyme that degrades the APOC3 mRNA-ASO duplex
- Degraded mRNA cannot be translated → less APOC3 protein is made
- Less APOC3 → lipoprotein lipase (LPL) is more active → triglycerides are cleared faster
The GalNAc conjugate on olezarsen directs it specifically to hepatocytes (liver cells), minimizing off-target effects.
Who Is Tryngolza For?
Tryngolza is FDA-approved for:
- Familial Chylomicronemia Syndrome (FCS): A rare autosomal recessive genetic disorder caused by mutations in LPL, APOC2, APOA5, LMF1, or GPIHBP1. Patients have triglycerides often >1,000 mg/dL and face severe recurrent pancreatitis. FCS has very few treatment options.
- Severe hypertriglyceridemia (triglycerides ≥500 mg/dL) to reduce pancreatitis risk — also sometimes called multifactorial chylomicronemia syndrome (MCS)
🧬 FCS vs. Severe Hypertriglyceridemia: FCS is a rare genetic disorder (1 in 1,000,000) with LPL completely absent or non-functional — triglycerides can reach 10,000+ mg/dL despite strict fat-free diets. Severe hypertriglyceridemia (more common) usually involves LPL dysfunction plus secondary factors like obesity, diabetes, or alcohol. Olezarsen addresses both by bypassing the need for functional LPL.
BALANCE Trial — The Evidence
The pivotal BALANCE trial studied olezarsen 80 mg monthly in patients with FCS (confirmed by genetic testing). Results at 6 months:
| Outcome | Olezarsen vs. Placebo |
|---|---|
| Triglyceride reduction | ~53% placebo-adjusted reduction |
| Patients with TG <500 mg/dL | ~77% (vs. ~14% placebo) |
| APOC3 reduction | ~79% |
| Pancreatitis events | Reduced in treated group |
Dosing and Administration
- Dose: 80 mg subcutaneous injection
- Frequency: Once monthly
- Injected into the abdomen, thigh, or upper arm
- Can be self-administered after proper training
- Triglyceride lowering begins within 1–2 weeks of first dose
Side Effects
Tryngolza is generally well tolerated. Common side effects include:
- Injection site reactions (mild bruising, redness)
- Arthralgia (joint pain)
- Fatigue
- Mild platelet count decreases — monitoring recommended
Unlike older therapies, olezarsen does not require significant dietary fat restriction in the same way as managing FCS traditionally requires. However, a low-fat diet is still recommended to support its effects.
Tryngolza vs. Redemplo — Key Differences
| Feature | Tryngolza (Olezarsen) | Redemplo (Plozasiran) |
|---|---|---|
| Mechanism | Antisense oligonucleotide (ASO) | siRNA |
| Target | APOC3 mRNA | APOC3 mRNA |
| Approval | March 2025 | December 2024 |
| Dosing | 80 mg monthly | 25 mg quarterly |
| TG reduction | ~53–70% | ~70–80% |
| Primary indication | FCS + severe hypertriglyceridemia | Severe hypertriglyceridemia |
Key Takeaways
- Tryngolza (olezarsen) silences APOC3 via antisense oligonucleotide, given once monthly by injection
- FDA-approved March 2025 for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia
- Reduces triglycerides ~53–70%; about 77% of FCS patients reached TG <500 mg/dL in trials
- Addresses a major unmet need in FCS — a condition with very few prior treatment options
- Monitor platelet counts; generally well tolerated otherwise
See a Specialist
Our board-certified endocrinologists can evaluate and manage your lipid and cardiovascular risk. Book with any of our providers:
Book an Appointment → or call 832-968-7003